Cost-effectiveness of Hepatic Arterial Chemoembolization for Colorectal Liver Metastases Refractory to Systemic Chemotherapy

Abstract

The cost-effectiveness of HACE for the treatment of CLM varies considerably according to the anticipated survival benefit. Results of future randomized controlled trials must demonstrate a survival benefit of nearly 5 months for HACE to meet the moderate cost-effectiveness standard of $50,000 per LY gained.